PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022

Transcription

1 Brochure More information from PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche s Pegasys and Merck s PegIntron) and ribavirin (e.g., Roche s Copegus and Merck s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck s Victrelis (boceprevir) or Vertex s Incivek (telaprevir). The entrance of nextgeneration HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable sideeffect profiles and decreased duration of therapy compared with the current standard of care. The anticipated main drivers of market growth during the forecast period include an increased awareness of the disease and the country s tendency to treat HCV once it is diagnosed. Standard interferon drugs are the current market leader in China. Our primary research revealed that Merck s Intron A (interferon alfa-2b) is the most commonly prescribed standard interferon in China, but that Roferon-A (interferon alfa-2a) and Kadmon s Infergen (interferon alfacon-1) are also used frequently. Standard interferon requires more-frequent dosing than peginterferon alpha, but standard interferon has been able to retain its market share in China in the face of competition from peginterferon due to its lower cost. Scope - Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in China from Analysis of the impact of key events as well the drivers and restraints affecting China HCV market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for HCV - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from in China Contents: List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview

2 3.1 Etiology and Pathophysiology Etiology Pathophysiology Prognosis 3.2 Symptoms 4 Disease Management 4.1 Diagnosis and Referral Overview 4.2 Treatment Overview 4.3 China Diagnosis Clinical Practice 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 5.3 Product Profiles Major Brands Incivek (telaprevir) Pegasys (peginterferon alfa-2a) PegIntron (peginterferon alfa-2b) Copegus, Rebetol, and Generic Ribavirin Therapeutic Class: Interferon 6 Opportunity and Unmet Need 6.1 Overview 6.2 Unmet Needs Unmet Need: Treatment Tolerability Unmet Need: Efficacy Unmet Need: Disease Awareness Unmet Need: Treatment Cost Unmet Need: Shorter Treatment Duration Unmet Need: Simplified Treatment Regimens 6.3 Unmet Needs Gap Analysis 6.4 Opportunities Opportunity: Pan-genotypic HCV Regimen Opportunity: Treatment of Underrepresented Patient Populations Opportunity: Involvement of Immune System 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development Simeprevir Faldaprevir and Faldaprevir plus BI Daclatasvir and Daclatasvir plus Asunaprevir Other Drug Classes 8 Market Outlook 8.1 China Forecast Key Events Drivers and Barriers 9 Appendix 9.1 Bibliography 9.2 Abbreviations 9.3 Methodology 9.4 Forecasting Methodology Percent Drug-Treated Patients Patient Warehousing Drugs Included in Each Therapeutic Class General Pricing Assumptions Individual Drug Assumptions Generic Erosion Selection of Pipeline Agents Pricing of Pipeline Agents 9.5 Physicians and Specialists Included in this Study 9.6 Survey of Prescribing Physicians 9.7 About the Authors Author

3 9.7.2 Global Head of Healthcare 9.8 About Us 9.9 Contact Us 9.10 Disclaimer 1.1 List of Tables Table 1: Modes of HCV Transmission Table 2: Symptoms of Acute and Chronic HCV Infection Table 3: HCV Genotypes Present in the 9MM Table 4: General Standard of Care by HCV Genotype Table 5: Treatment Guidelines for HCV by Country Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 Table 7: Leading Treatments for HCV, 2012 Table 8: Product Profile Incivek Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) Table 11: Common Incivek Adverse Drug Reactions Table 12: Incivek SWOT Analysis, 2012 Table 13: Product Profile Pegasys Table 14: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b Table 15: Pegasys SWOT Analysis, 2012 Table 16: Product Profile PegIntron Table 17: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b Table 18: PegIntron SWOT Analysis, 2012 Table 19: Effect of Addition of Ribavirin to Peginterferon HCV Therapy Table 20: Ribavirin SWOT Analysis, 2012 Table 21: Summary of Minor Therapeutic Classes, 2012 Table 22: Overall Unmet Needs Current Level of Attainment Table 23: Clinical Unmet Needs Gap Analysis, 2012 Table 24: HCV Pipeline, 2012 Table 25: Comparison of Therapeutic Classes in Development for HCV, 2012 Table 26: Janssen s Simeprevir Ongoing Clinical Trials of Interest Table 27: Product Profile Simeprevir Table 28: PILLAR Clinical Trial Results Table 29: Adverse Events Observed in PILLAR Clinical Trial Table 30: Simeprevir SWOT Analysis, 2012 Table 31: Boehringer Ingelheim s Faldaprevir Ongoing Clinical Trials of Interest Table 32: Product Profile Faldaprevir Table 33: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) Table 34: Faldaprevir SWOT Analysis, 2012 Table 35: Bristol-Myers Squibb s Daclatasvir Ongoing Clinical Trials of Interest Table 36: Product Profile Daclatasvir Table 37: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) Table 38: Daclatasvir and Asunaprevir Quad Therapy Efficacy Table 39: Daclatasvir Triple Therapy Adverse Events Table 40: Daclatasvir SWOT Analysis, 2012 Table 41: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) Table 42: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) Table 43: Sales Forecasts ($m) for HCV in China, Table 44: Key Events Impacting Sales for HCV in China, 2012 Table 45: Chinese HCV Market Drivers and Barriers, 2012 Table 46: Physicians Surveyed, By Country 1.2 List of Figures Figure 1: HCV Genome and Polyprotein Composition Figure 2: HCV Lifecycle Overview Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, Figure 4: Sales for HCV Therapeutics in China by Drug Class, Ordering: Order Online -

4 Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

5 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022 Web Address: Office Code: Product Formats Please select the product formats and quantity you require: SC Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 4995 USD 9990 USD * The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

6 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World